Although it will be impacted in the short term by the COVID-19 pandemic, the biosurgical agent market in the US will grow at a modest rate through 2029, primarily driven by growing surgical procedure volumes, rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the US across a 10-year period.
The COVID-19 pandemic will affect the US biosurgical agent market.
Which surgical specialties will be most impacted?
At what pace is the biosurgical agent market expected to recover?
Increasing surgical procedure volumes in the US will largely dictate the growth of the overall market.
Which surgical specialties have the largest market size for biosurgical agents?
How will declining procedure volumes in certain surgical specialties affect market growth?
Product penetration by surgical specialty will influence overall market trends.
Which specialty type has seen the highest overall penetration of biosurgical agents?
Which biosurgical agent materials are most popular and drive unit sales within each specialty?
What product type accounts for the largest portion of the overall market?
Which product types will exhibit the greatest market growth and why?
Product innovation and the expansion of approved indications will support market growth.
What new products are anticipated to enter the market and how will they be received?
How will new indications impact market growth and surgeon adoption?
Which companies have obtained expanded approvals for new indications?
Beyond product innovation and expanding the approved indications of their products, what competitive strategies are vendors prioritizing in this space?
- Biosurgical Agents - Market Insights - US
Author(s): Sumit Jain, MS Pharm
Sumit Jain is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.